Mechanisms of tumour invasion and metastasis: Emerging targets for therapy

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 2, 2002, Pages 217-233

  Price, John T ^a   Thompson, Erik W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adhesion; Cadherins; Focal adhesion kinase; Growth factors; Integrins; Invasion; Matrix metalloproteinases; Metastasis; Migration; Phosphatidylinositol 3 kinase; Phospholipase C; Proteases; u PAR

Indexed keywords

ALPHA5 INTEGRIN; ALPHA6 INTEGRIN; ANTINEOPLASTIC AGENT; CADHERIN; CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GELATINASE A; GELATINASE B; GUANOSINE TRIPHOSPHATASE; INTERSTITIAL COLLAGENASE; JANUS KINASE; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PHOSPHOLIPASE C; PLASMINOGEN ACTIVATOR; PROTEIN CDC42; PROTEIN TYROSINE KINASE; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; SCATTER FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE KINASE RECEPTOR; UROKINASE;

ANGIOGENESIS; ANIMAL CELL; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; METASTASIS; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CADHERINS; CELL ADHESION; CELL MOVEMENT; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INTEGRINS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHOSPHOLIPASE C; PHOSPHOLIPASE C GAMMA; PLASMINOGEN ACTIVATORS; PROTEIN-TYROSINE KINASES; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 0036244198     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.2.217     Document Type: Review

References (173)

1. Cancer metastasis: Experimental approaches, theoretical concepts, and impacts for treatment strategies
2. The biochemistry of cancer dissemination
3. Cancer invasion and metastasis: Positive and negative regulatory elements
4. Molecular insights into cancer invasion: Strategies for prevention and intervention
5. Supramolecular assembly of basement membranes
6. Tissue structure, nuclear organization, and gene expression in normal and malignant breast
7. The influence of the microenvironment on the malignant phenotype
8. The microenvironment of the tumour-host interface
9. Angiogenesis and tumor metastasis
10. The multiple roles of tumour stroma
11. MMP-9 Supplied by bone marrow-derived cells contributes to skin carcinogenesis
12. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis
13. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter
14. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis
15. Tumour dormancy: Findings and hypotheses from clinical research on breast cancer
16. Integrin signaling
17. Integrins: Versatility, modulation, and signaling in cell adhesion
18. Integrins and cancer
19. Integrin cell adhesion receptors and the concept of agonism
20. Integrins and GTPases in tumour cell growth, motility and invasion
21. Integrins and anoikis
22. Integrins and vascular extracellular matrix assembly
23. Role of integrins in angiogenesis
24. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen
25. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane Type 1 matrix metalloproteinase through beta1 integrin
26. Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen
27. Integrin alpha 2 beta 1 is a positive regulator of collagenase (MMP-1) and collagen alpha 1(I) gene expression
28. Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction
29. Increased expression of alpha2beta1-integrin in the peritoneal dissemination of human gastric carcinoma
30. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells
31. Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells
32. Alpha6 integrin expression in esophageal carcinoma
33. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival
34. Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells
35. Integrin alpha6beta1 role in metastatic behavior of human pancreatic carcinoma cells
36. Prognostic value of alpha6beta4 integrin expression in breast carcinomas is affected by laminin production from tumor cells
37. Laminin regulates a tumor cell chemotaxis receptor through the laminin-binding integrin subunit alpha 6
38. Suppression of mouse melanoma metastasis by EA-1, a monoclonal antibody specific for alpha 6 integrins
39. The integrin, alpha6beta1, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells
40. An epitope on VLA-6 (alpha6beta1) integrin involved in migration but not adhesion is required for extravasation of murine melanoma B16F1 cells in liver
41. The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures
42. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion
43. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth
44. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling
45. The alphavbeta6 integrin induces gelatinase B secretion in colon cancer cells
46. Alphavbeta6 integrin promotes invasion of squamous carcinoma cells through upregulation of matrix metalloproteinase-9
47. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis
48. The role of TGFbeta in human cancers
49. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta
50. Role of transforming growth factor beta in cancer
51. Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor)
52. The role of alpha v-integrins in tumour progression and metastasis
53. The role of the integrin vitronectin receptor, alphavbeta3 in melanoma metastasis
54. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
55. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
56. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity
57. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo
58. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma
59. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen
60. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway
61. Synthetic alphavbeta3 antagonists inhibit insulin-like growth factor-I-stimulated smooth muscle cell migration and replication
62. Small molecule alpha(v) integrin antagonists: Novel anticancer agents
63. MT1-MMP initiates activation of pro-MMP-2 and integrin alphav beta3 promotes maturation of MMP-2 in breast carcinoma cells
64. Disruption of matrix metalloproteinase 2 binding to integrin alphavbeta3 by an organic molecule inhibits angiogenesis and tumor growth in vivo
65. Targeted antiangiogenic therapy for cancer using vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3
66. A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer
67. Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas
68. Cadherin cell adhesion molecules in differentiation and embryogenesis
69. A causal role for E-cadherin in the transition from adenoma to carcinoma
70. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells
71. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model
72. Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness
73. The E-cadherin/catenin complex in invasion and metastasis
74. The small GTPases Rho and Rac are required for the establishment of cadherin-dependent cell-cell contacts
75. Inhibition of invasion of epithelial cells by Tiam 1-Rac signaling
76. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1
77. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas
78. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers
79. Mutations of the E-cadherin gene in human gynecologic cancers
80. Prognostic value of cadherin-associated molecules (alpha-, beta, and gamma-catenins and p120cas) in bladder tumors
81. Functional interaction of beta-catenin with the transcription factor LEF-1
82. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos
83. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
84. Stabilization of beta-catenin by genetic defects in melanoma cell lines
85. Beta-catenin signaling and cancer
86. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast
87. Specific protection against breast cancers by cyclin D1 ablation
88. Correlation of beta-catenin and cyclin D1 expression in colon cancers
89. The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas
90. Frequent hypermethylation of the 5′ CpG island of E-cadherin in esophageal adenocarcinoma
91. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma
92. Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer
93. Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells
94. Inhibitory effects of indole-3-carbinol on invasion and migration in human breast cancer cells
95. Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion
96. N-cadherin promotes adhesion between invasive breast cancer cells and the stroma
97. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression
98. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis
99. How matrix metalloproteinases regulate cell behavior
100. Interstitial collagenases as markers of tumor progression
101. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity
102. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis
103. Transmembrane/cytoplasmic domain-mediated membrane Type 1-matrix metalloprotease docking to invadopodia is required for cell invasion
104. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
105. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
106. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
107. Regulation of cell invasion and morphogenesis in a three-dimensional Type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3
108. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice
109. MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells
110. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells
111. The epithelial to mesenchymal transition and metastatic progression in carcinoma
112. Recent advances in the field of matrix metalloproteinase inhibitors
113. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
114. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
115. Human endothelial gelatinases and angiogenesis
116. Towards the therapeutic targeting of matrix metalloproteinases in breast cancer
117. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis
118. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosylphosphatidylinositol
119. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
120. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression
121. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
122. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta
123. Role of urokinase receptor and caveolin in regulation of integrin signaling
124. Mechanisms of signaling through urokinase receptor and the cellular response
125. Urokinase receptor: A molecular organizer in cellular communication
126. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner
127. Prevention of metastasis by inhibition of the urokinase receptor
128. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines
129. Inhibition of colon cancer metastasis by a 3′-end antisense urokinase receptor mRNA in a nude mouse model
130. Peptide-derived antagonists of the urokinase receptor affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation
131. Molecular switches in metastasis
132. The biology of erbB-2/neu/HER-2 and its role in cancer
133. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
134. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
135. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases
136. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells
137. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase
138. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)
139. Herceptin (trastuzamab) in advanced breast cancer
140. Phosphatidylinositol 3-kinase
141. Ras activation of phosphatidylinositol 3-kinase and Akt
142. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism
143. Prolactin as a chemoattractant for human breast carcinoma
144. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process
145. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration
146. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase
147. Phosphoinositide 3-kinase as an upstream regulator of the small GTP-binding protein Rac in the insulin signaling of membrane ruffling
148. Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling
149. Specific requirement for the p85-p110alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells
150. Rapid lamellipodia formation in nerve growth factor-stimulated PC12 cells is dependent on Rac and P13K activity
151. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion
152. Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion
153. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1
154. Differentiation-induced increase in Clostridium botulinum C3 exoenzyme-catalyzed ADP-ribosylation of the small GTP-binding protein Rho
155. Rho GTPases: Molecular switches that control the organization and dynamics of the actin cytoskeleton
156. Rho GTPases are over-expressed in human tumors
157. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K
158. Motility and invasion are differentially modulated by Rho family GTPases
159. Genomic analysis of metastasis reveals an essential role for RhoC
160. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas
161. Dependence of fibroblast migration on actin severing activity of gelsolin
162. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells
163. Molecular inhibition of phospholipase C-gamma signaling abrogates DU-145 prostate tumor cell invasion
164. Inhibition of the EGF-induced activation of phospholipase C-gammal by a single chain antibody fragment
165. Focal adhesion kinase: A regulator of focal adhesion dynamics and cell movement
166. Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines
167. Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK
168. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice
169. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis
170. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells
171. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells
172. Focal adhesion kinase promotes phospholipase C-gamma1 activity
173. Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2